Figure 2

Antigen-driven bystander effect by Th1 pretreatment also enhanced epicutaneously induced Th2 immune response to a new protein antigen. (A) (B) (C) Group of mice (Four per group) were non-pretreated (PBS, no) or subcutaneously (sc) pretreated with BSA and CFA adjuvant on day -21. They were all epicutaneously sensitized with BSA and OVA (no, sc) or PBS (PBS) on day 1–5. On day 11, draining LNs were obtained (A). On day 22 spleens were taken (B). In vitro reactivation culture with OVA was performed. Cytokines contents of 48 h-supernatants were measured by ELISA. Results were shown as mean ± SEM. (C) On day 22~26, all mice received another course of OVA patch application. On day 29, blood were collected and serum OVA-specific IgG2a and IgE were determined by ELISA. Three independent experiments were performed with similar results. One representative results are shown. (D) Groups of mice (four per group) were immunized by subcutaneous injection with BSA and CFA adjuvant (sc) or BSA and alum adjuvants (ip) three weeks before their spleens were obtained. In vitro reactivation culture of spleen cells with BSA was performed. Cytokine contents of 48 h-supernatants were measured by ELISA. Results were shown as mean ± SEM. Three independent experiments were performed with similar results. One representative results are shown.